Accutane / Isotretinoin Treatment in New York City

Depression and other psychiatric symptoms have been reported in patients taking isotretinoin, which is why mental-health history and new symptoms should be taken seriously.

Large population-level studies have not demonstrated an increased overall risk of psychiatric disorders attributable to isotretinoin. Patients with a history of depression should discuss that history with their dermatologist, and meaningful mood changes during treatment should be reported.

The possible relationship between isotretinoin and inflammatory bowel disease has been studied for many years. Current large studies and meta-analyses have not shown an increased overall risk of IBD associated with isotretinoin.

Persistent abdominal pain, rectal bleeding, severe diarrhea or other significant gastrointestinal symptoms should still be reported and evaluated rather than ignored.

Treatment time varies. There is no single isotretinoin regimen that fits every patient. Some patients may be treated longer with lower daily doses, while higher daily doses may allow a shorter overall course.

Follow-up allows the dose and treatment timeline to be adjusted according to response, side effects and the individual clinical situation.

Pregnancy exposure to isotretinoin can cause miscarriage and severe fetal abnormalities. Pregnancy must be avoided during treatment and for the required period after the final dose.

Patients who can become pregnant must follow the current iPLEDGE pregnancy-prevention and testing requirements.

iPLEDGE is the FDA Risk Evaluation and Mitigation Strategy used for all FDA-approved isotretinoin products in the United States because of the medication's embryo-fetal toxicity.

Patients, prescribers and pharmacies participate in the program. Because program procedures can change, we guide patients through the requirements that are current at the time of treatment.

Isotretinoin must not be taken during pregnancy. It is also not approved for children younger than 12 years old.

Other medical conditions do not always mean that isotretinoin is prohibited, but liver disease, significant lipid abnormalities, diabetes, bone-health concerns and other relevant medical problems may affect whether treatment is appropriate and how closely monitoring is performed.

Patients should tell their dermatologist about all medications and supplements. Vitamin A supplements should be avoided while taking isotretinoin.

Tetracycline antibiotics should not be used together with isotretinoin because the combination can increase the risk of intracranial hypertension.

Laboratory monitoring may include triglycerides, cholesterol and liver-related testing. The schedule can be individualized according to baseline results, dose, medical history and risk factors.

Sometimes. The old rule that every cosmetic procedure must automatically be delayed for many months after isotretinoin is no longer supported for many procedures.

The decision depends on the specific procedure, treatment intensity, isotretinoin exposure, skin type and healing risk. Fully ablative resurfacing and mechanical dermabrasion still require greater caution.

Yes. Many patients experience prolonged remission, but recurrence is possible. Acne severity, hormonal factors, cumulative exposure and individual acne biology can influence long-term outcome.

Isotretinoin treats active acne and may reduce the formation of additional scars by preventing new inflammatory lesions. It does not remove established structural acne scars.

Once the acne is controlled, scar treatment can be planned separately.